These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 36200799)

  • 1. Assessment of BRAF V600E (VE1) immunochemistry for the detection of BRAF V600E mutation in non-small cell lung carcinoma cytology specimens.
    Garcia A; Rivera Rolon MDM; Barkoh B; Chen W; Luthra R; Roy-Chowdhuri S
    Cancer Cytopathol; 2023 Jan; 131(1):50-57. PubMed ID: 36200799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical Study Using Monoclonal VE1 Antibody Can Substitute the Molecular Tests for Apprehension of BRAF V600E Mutation in Patients with Non-small-Cell Lung Carcinoma.
    Karbel HAE; Ejam SS; Naji AZ
    Anal Cell Pathol (Amst); 2019; 2019():2315673. PubMed ID: 31781475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemistry with Anti-BRAF V600E (VE1) Mouse Monoclonal Antibody is a Sensitive Method for Detection of the BRAF V600E Mutation in Colon Cancer: Evaluation of 120 Cases with and without KRAS Mutation and Literature Review.
    Dvorak K; Higgins A; Palting J; Cohen M; Brunhoeber P
    Pathol Oncol Res; 2019 Jan; 25(1):349-359. PubMed ID: 29127628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ultra-deep sequencing confirms immunohistochemistry as a highly sensitive and specific method for detecting BRAF V600E mutations in colorectal carcinoma.
    Rössle M; Sigg M; Rüschoff JH; Wild PJ; Moch H; Weber A; Rechsteiner MP
    Virchows Arch; 2013 Nov; 463(5):623-31. PubMed ID: 24085553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Value of immunohistochemistry in the detection of BRAF(V600E) mutations in fine-needle aspiration biopsies of papillary thyroid carcinoma.
    Zimmermann AK; Camenisch U; Rechsteiner MP; Bode-Lesniewska B; Rössle M
    Cancer Cytopathol; 2014 Jan; 122(1):48-58. PubMed ID: 24039206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of BRAF V600E Status in Colorectal Carcinoma: Tissue-Specific Discordances between Immunohistochemistry and Sequencing.
    Estrella JS; Tetzlaff MT; Bassett RL; Patel KP; Williams MD; Curry JL; Rashid A; Hamilton SR; Broaddus RR
    Mol Cancer Ther; 2015 Dec; 14(12):2887-95. PubMed ID: 26438153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in primary lung adenocarcinoma Caucasian patients.
    Ilie M; Long E; Hofman V; Dadone B; Marquette CH; Mouroux J; Vignaud JM; Begueret H; Merlio JP; Capper D; von Deimling A; Emile JF; Hofman P
    Ann Oncol; 2013 Mar; 24(3):742-8. PubMed ID: 23131393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world assessment of the BRAF status in non-squamous cell lung carcinoma using VE1 immunohistochemistry: A single laboratory experience (LPCE, Nice, France).
    Hofman V; Benzaquen J; Heeke S; Lassalle S; Poudenx M; Long E; Lantéri E; Bordone O; Lespinet V; Tanga V; Bonnetaud C; Bille Y; Ilié M; Marquette C; Barlesi F; Boutros J; Hofman P
    Lung Cancer; 2020 Jul; 145():58-62. PubMed ID: 32408133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discrepancy between immunohistochemistry and sequencing for BRAF V600E in odontogenic tumours: Comparative analysis of two VE1 antibodies.
    Oh KY; Cho SD; Yoon HJ; Lee JI; Hong SD
    J Oral Pathol Med; 2021 Jan; 50(1):85-91. PubMed ID: 32939809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Usefulness of immunohistochemistry for the detection of the BRAF V600E mutation in Japanese lung adenocarcinoma.
    Sasaki H; Shimizu S; Tani Y; Shitara M; Okuda K; Hikosaka Y; Moriyama S; Yano M; Fujii Y
    Lung Cancer; 2013 Oct; 82(1):51-4. PubMed ID: 23927882
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Ahn HY; Lee CH; Lee MK; Eom JS; Jeong YJ; Kim YD; Cho JS; Lee J; Lee SJ; Shin DH; Kim A
    Medicina (Kaunas); 2023 Jun; 59(6):. PubMed ID: 37374289
    [No Abstract]   [Full Text] [Related]  

  • 12. The immunocytochemical expression of VE-1 (BRAF V600E-related) antibody identifies the aggressive variants of papillary thyroid carcinoma on liquid-based cytology.
    Straccia P; Brunelli C; Rossi ED; Lanza P; Martini M; Musarra T; Lombardi CP; Pontecorvi A; Fadda G
    Cytopathology; 2019 Sep; 30(5):460-467. PubMed ID: 30875124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of 2 monoclonal antibodies for immunohistochemical detection of BRAF V600E mutation in malignant melanoma, pulmonary carcinoma, gastrointestinal carcinoma, thyroid carcinoma, and gliomas.
    Routhier CA; Mochel MC; Lynch K; Dias-Santagata D; Louis DN; Hoang MP
    Hum Pathol; 2013 Nov; 44(11):2563-70. PubMed ID: 24071017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Specific immunohistochemical detection of the BRAF V600E mutation in primary and metastatic papillary thyroid carcinoma.
    Zhu X; Luo Y; Bai Q; Lu Y; Lu Y; Wu L; Zhou X
    Exp Mol Pathol; 2016 Feb; 100(1):236-41. PubMed ID: 26795218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRAFV600E mutation analysis by immunohistochemistry in patients with thoracic metastases from colorectal cancer.
    Ilie MI; Long-Mira E; Hofman V; Mouroux J; Vignaud JM; Gauchotte G; Begueret H; Merlio JP; Emile JF; Hébuterne X; Hofman P
    Pathology; 2014 Jun; 46(4):311-5. PubMed ID: 24798160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical detection of BRAF V600E mutant protein using the VE1 antibody in colorectal carcinoma is highly concordant with molecular testing but requires rigorous antibody optimization.
    Kuan SF; Navina S; Cressman KL; Pai RK
    Hum Pathol; 2014 Mar; 45(3):464-72. PubMed ID: 24529329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Utility and evaluation of immunohistochemical detection of BRAF V600E mutation in melanoma].
    Lyu JJ; Kong YY; Cai X; Shen XX; Lu YW; Ren M
    Zhonghua Bing Li Xue Za Zhi; 2017 Aug; 46(8):548-552. PubMed ID: 28810295
    [No Abstract]   [Full Text] [Related]  

  • 18. VE1 immunohistochemical detection of the BRAF V600E mutation in thyroid carcinoma: a review of its usefulness and limitations.
    Na JI; Kim JH; Kim HJ; Kim HK; Moon KS; Lee JS; Lee JH; Lee KH; Park JT
    Virchows Arch; 2015 Aug; 467(2):155-68. PubMed ID: 25894433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selection Strategies and Practical Application of BRAF V600E-Mutated Non-Small Cell Lung Carcinoma.
    Hwang I; Choi YL; Lee H; Hwang S; Lee B; Yang H; Chelakkot C; Han J
    Cancer Res Treat; 2022 Jul; 54(3):782-792. PubMed ID: 34844291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of BRAF V600E mutation-specific immunohistochemistry in pediatric Langerhans cell histiocytosis.
    Ballester LY; Cantu MD; Lim KPH; Sarabia SF; Ferguson LS; Renee Webb C; Allen CE; McClain KL; Mohila CA; Punia JN; Roy A; López-Terrada DH; John Hicks M; Fisher KE
    Hematol Oncol; 2018 Feb; 36(1):307-315. PubMed ID: 28219109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.